Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 15/20 | 0.56 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5641494 | 0.80 | NTRK1 (0.64) | NTRK1JAK2POLB | |
| SCHEMBL3091765 | 0.75 | NTRK1 (0.61) | NTRK1ICAM1TSHR | |
| SCHEMBL5641550 | 0.75 | NTRK1 (0.51) | NTRK1 | |
| SCHEMBL3096241 | 0.73 | NTRK1 (0.47) | NTRK1TSHR | |
| SCHEMBL5641273 | 0.72 | NTRK1 (0.66) | NTRK1JAK2 | |
| SCHEMBL5640340 | 0.72 | NTRK1 (1.00) | NTRK1JAK2POLB | |
| SCHEMBL5637836 | 0.71 | NTRK1 (0.61) | NTRK1JAK2MAPK1 | |
| SCHEMBL5642992 | 0.71 | NTRK1 (1.00) | NTRK1 | |
| SCHEMBL5641759 | 0.70 | NTRK1 (1.00) | NTRK1JAK2TSHR | |
| SCHEMBL5642011 | 0.69 | NTRK1 (0.50) | NTRK1JAK2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7276602-B2 | Isothiazole derivatives useful as anticancer agents | PFIZER INC (US) | 2007-10-02 | — | — | US | disclosed |
| US-20040152691-A1 | Isothiazole derivatives useful as anticancer agents | PFIZER INC | 2004-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152691-A1 | Isothiazole derivatives useful as anticancer agents | TP53, ACIN1, CDKN1A | NTRK1 4460/4885EPHX1 2832/4885JAK2 1478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.